Navigation Links
A New Therapy to Protect Cancer Patients Against Infertility

The 23rd annual conference of the European Society of Human Reproduction and Embryology today revealed a promising new therapy for protecting the fertility of women with cancer and auto-immune diseases such as lupus.

Dr. Kate Stern, Research Director of the Royal Womens Hospital, Melbourne, Australia, told the conference that her pilot study had shown gonadotropin-releasing hormone (GnRH) antagonists were likely to be able to protect the ovary in women receiving potentially toxic doses of chemotherapy. We are now hoping to carry out a randomised controlled trial to assess the long term protective effect of this treatment, she said.

GnRH analogues are commonly used in the management of womens disorders that are dependent on oestrogen production, and in IVF therapies. Dr. Stern and her team studied women between the ages of 18 and 35 years who were due to receive high doses of cyclophosphamide, a chemotherapy drug.

They knew that GnHR analogues were already used for the temporary suppression of ovulation in infertility treatment, so reasoned that it would be possible to use it to shut down the ovaries temporarily during the time that chemotherapy was administered, and hence protect them from the effect of the drugs.

The women were given the GnRH antagonist cetrorelix by 3 subcutaneous injections, each of them four days apart, concurrently with their chemotherapy.

The scientists observed that there was evidence that ovarian function was suppressed, but that this returned to normal after chemotherapy stopped. Follicle stimulating hormone levels were up in 73% of the patients, but these also subsequently returned to normal. 94% of the patients resumed spontaneous ovulation and menses within 12 months.

We believe that using GnRH antagonists in this way could reduce the side effects of chemotherapy over a long period, said Dr. Stern. Other studies have tried to analyse whether similar tr
'"/>




Page: 1 2

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
(Date:7/25/2008)...er & Olsen LLP has filed a,class action lawsuit ag..."Company") (Nasdaq: ARTC ) and certain of its off...istrict of Texas on behalf of all persons or,entit... January 24, 2008,through July 18, 2008 (the "Comm...or entities who purchased call options or sold put...
(Date:7/25/2008)... therapy may be due to genetic factors , ... challenges the long-held belief that the hepatiti...y to restore itself after HIV patients are treated.... , From 50 percent to 90 percent of HIV-infect...ous drug use is the main cause of both types of in...
(Date:7/25/2008)...ity.com announces the,availability of Trade Alerts... all of the daily trading notes for free by visiti...erts include: DUSA Pharmaceuticals Inc. (Nasdaq: ... MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Adolor Corp....) and,Abaxis Inc. (Nasdaq: ABAX )., Join investo...
(Date:7/25/2008)...mprovements in Members, Health, ATLANTA, July 25 ...h,care quality management solutions for health pla...nto a long-term agreement with Wellmark, Inc. to,c...lity(SM) Incent and,Reward Best Practices initiati...are clinicians to promote improved quality health ...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...by Japanese government and produced by Unicef, the... Food and Agriculture// Organization, features Jac...untries and some colorful origami birds urging chi...In the advertisement shot in English at Sha Tin Ju...
...Britain and promoted by pop star Beyonce Knowles, ...ays.// All over the country, health shops are se...he shelves after pop star Beyonce Knowles said she... her latest film. The syrup, is said to be made ...
...desh to help malnourished children is yet to make ...led to aid the 5.7 million malnourished children o... age, Grassroots Features reported. Two-and-a-hal...riya tribal couple's daughter from Amolpath villag...
...iversity published his findings on a better substi...his month//. According to peer-reviewed research p...the kind of immune response doctors were looking f...ing, the vaccine was given to 100 volunteers at fo...
Other Medicine News:Health News:Scheme for Combating Malnourishment in MP Children Yet to Pick Up 2
(Date:7/22/2008)...a multi-center 293-patient European, trial -, h...ymbol: CYT, MONTREAL, July 22 /PRNewswire-FirstCa...ader in cryotherapy products to treat cardiac,arrh...resented from three,European study centers using t...ublished earlier today in the Journal of the Ameri...
(Date:7/22/2008)...s Development Initiative bring MJFF,s,current acti...nuary 20,2009, NEW YORK, July 22 /PRNewswire-USN...ry of transformative treatments and a cure for Par...r Parkinson,s Research has awarded,$2.7 million in... awards,were granted under MJFF,s Therapeutics Dev...
(Date:7/22/2008)...nd Efficacy of Treating Patients with ... and YONGIN-SI, South Korea, July 22 /PRNewswire/ ...ntario), and its South,Korean partner Green Cross ...Phase I clinical trial of its first-in-class lead ...ell-tolerated and resulted in clear,anti-cancer ef...
(Date:7/22/2008)... and Apidra(R) Resulted in Significant, Reductions... the Algorithm Us...sults from the "Adjust to,Target in Type 2 Diabete...e,Counting for Adjustment of Mealtime Insulin Glul...tes Association,s (ADA) medical journal,Diabetes ...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 1Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 2Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 3Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 4Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 5Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed Refractory CLL Who Achieve Complete Remission 1016 6TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non Hodgkins Lymphoma 1012 1TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non Hodgkins Lymphoma 1012 2TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non Hodgkins Lymphoma 1012 3TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non Hodgkins Lymphoma 1012 4TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non Hodgkins Lymphoma 1012 5Private Equity Firms Acquire American Laser Centers 7939 1Private Equity Firms Acquire American Laser Centers 7939 2Brooks and the University of Florida Reach Research Agreement 7935 1Brooks and the University of Florida Reach Research Agreement 7935 2
...merican Academy of Neurology Annual Meeting,Show A...res, BOSTON, May 01, 2007 /PRNewswire/ -- Data fro...can Academy of Neurology (AAN),meeting suggest tha...ormulation of Lamictal(R) (lamotrigine) is effecti...ilepsy with and without,secondary generalization. ...
...omen published today shows reduction of 70,percent...s, EAST HANOVER, N.J., May 02, 2007 /PRNewswire/ -...c acid) Injection significantly,reduced the incide...er three years in women with postmenopausal osteop...land Journal of Medicine,marks the first time tha...
Other Medicine Technology:New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 2New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 3New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 4New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6
Specially designed for rugged use; perfect tool with power and endurance. Balance of weight and power helps reduce user fatigue. Internally lubricated for longer serivce. Switch is designed and place
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability.
...he osteotomy staples is quite similar to the type ...e the inner position of the anti recoil contours a...lique staples). There are 3 kinds of staples: 1.... staples can have 3 different widths: 20mm, 26 mm ...
...e Barium Sulfate USP is specifically designed to p...pabilities for todays medical professionals who ad...y. Comprised of a uniform particle size, Biotrace ...lting in a consistent visualization of bone cement...
Medicine Products: